OTCMKTS:GNMSF Genmab A/S (GNMSF) Stock Price, News & Analysis $367.00 0.00 (0.00%) As of 10/14/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsFinancialsNews and TrendsSEC FilingsShort Interest About Genmab A/S Stock (OTCMKTS:GNMSF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Genmab A/S alerts:Sign Up Key Stats Today's Range$367.00▼$367.0050-Day Range$295.00▼$390.5152-Week Range$232.34▼$396.97VolumeN/AAverage Volume3,032 shsMarket Capitalization$22.60 billionP/E Ratio28.78Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Genmab A/S is a Danish biotechnology company focused on discovering, developing and commercializing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company develops therapeutic antibodies and antibody formats designed to engage the immune system, target disease-specific biology and potentially improve treatment outcomes. Genmab’s technology platforms include DuoBody, which enables the development of bispecific antibodies, as well as HexaBody and other antibody-engineering technologies. Its research and development activities have contributed to medicines including DARZALEX (daratumumab) for multiple myeloma, RYBREVANT (amivantamab) for certain lung cancers, and EPKINLY (epcoritamab) for certain B-cell lymphomas. Genmab has developed these and other products through collaborations with global pharmaceutical companies, including Johnson & Johnson and AbbVie. Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab serves international markets through research, development, partnerships and commercialization activities in Europe, North America and other regions. The company is led by President and Chief Executive Officer Jan van de Winkel, who has been associated with Genmab’s leadership since the company’s early development.AI Generated. May Contain Errors. Read More Genmab A/S Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks20th Percentile Overall ScoreGNMSF MarketRank™: 0.975960282205 of 5 starsGenmab A/S scored higher than 20% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Genmab A/S. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Genmab A/S is 28.78, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.86.Price to Earnings Ratio vs. SectorThe P/E ratio of Genmab A/S is 28.78, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.95.Price to Book Value per Share RatioGenmab A/S has a P/B Ratio of 4.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Genmab A/S's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.18% of the float of Genmab A/S has been sold short.Short Interest Ratio / Days to CoverGenmab A/S has a short interest ratio ("days to cover") of 296.59, which indicates bearish sentiment.Change versus previous monthShort interest in Genmab A/S has recently decreased by 44.38%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGenmab A/S does not currently pay a dividend.Dividend GrowthGenmab A/S does not have a long track record of dividend growth. News and Social Media2.5 / 5News SentimentN/A News SentimentGenmab A/S has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Genmab A/S this week, compared to 1 article on an average week. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Genmab A/S insiders have not sold or bought any company stock.Percentage Held by Insiders1.54% of the stock of Genmab A/S is held by insiders.Percentage Held by InstitutionsGenmab A/S has minimal institutional ownership at this time.Read more about Genmab A/S's insider trading history. Receive GNMSF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GNMSF Stock News HeadlinesGenmab Grants Restricted Stock Units to Board After Extraordinary General MeetingOctober 7, 2026 | tipranks.comGenmab A/S (OTCMKTS:GNMSF) Shares Gap Up - Here's What HappenedOctober 6, 2026 | americanbankingnews.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.October 15 at 1:00 AM | Profits Run (Ad)GMAB jumps as Genmab posts positive Phase 3 lymphoma dataOctober 5, 2026 | quiverquant.comQGenmab A/S (OTCMKTS:GNMSF) Sets New 12-Month High - What's Next?October 5, 2026 | americanbankingnews.comGenmab Discloses Darwin Global as 5.11% Major ShareholderOctober 2, 2026 | tipranks.comMajor Shareholder AnnouncementOctober 2, 2026 | markets.businessinsider.comGenmab Updates Articles of Association, Preserves Broad Capital-Raising PowersSeptember 9, 2026 | tipranks.comSee More Headlines GNMSF Stock Analysis - Frequently Asked Questions How have GNMSF shares performed this year? Genmab A/S's stock was trading at $314.00 at the beginning of 2026. Since then, GNMSF shares have increased by 16.9% and is now trading at $367.00. How were Genmab A/S's earnings last quarter? Genmab A/S (OTCMKTS:GNMSF) issued its quarterly earnings data on Tuesday, February, 17th. The company reported $0.55 EPS for the quarter, missing analysts' consensus estimates of $3.10 by $2.55. The firm earned $1.06 billion during the quarter, compared to the consensus estimate of $1.05 billion. Genmab A/S had a trailing twelve-month return on equity of 14.89% and a net margin of 19.08%. How do I buy shares of Genmab A/S? Shares of GNMSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Genmab A/S own? Based on aggregate information from My MarketBeat watchlists, some other companies that Genmab A/S investors own include Genmab A/S (GMAB), Novo Nordisk A/S (NVO), Bavarian Nordic (BVNRY), GENMAB A/S/S (GMXAY), Micron Technology (MU), Alibaba Group (BABA) and Cigna Group (CI). Company Calendar Last Earnings2/17/2026Today10/15/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:GNMSF CIK1434265 Webwww.genmab.com Phone(457) 020-2728Fax45-7020-2729Employees3,029Year Founded1999Profitability EPS (Trailing Twelve Months)$12.75 Trailing P/E Ratio28.78 Forward P/E RatioN/A P/E GrowthN/ANet Income$963 million Net Margins19.08% Pretax Margin21.93% Return on Equity14.89% Return on Assets7.73% Debt Debt-to-Equity Ratio0.81 Current Ratio2.46 Quick Ratio2.44 Sales & Book Value Annual Sales$3.72 billion Price / Sales6.07 Cash Flow$15.65 per share Price / Cash Flow23.45 Book Value$88.49 per share Price / Book4.15Miscellaneous Outstanding Shares61,570,000Free Float60,622,000Market Cap$22.60 billion OptionableNot Optionable Beta0.75 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (OTCMKTS:GNMSF) was last updated on 10/14/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genmab A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Genmab A/S With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
